Creative Medical Technology Holdings, Inc. (CELZ) |
|
0.512 -0.041 (-7.35%)
|
02-03 14:19 |
|
Open: |
0.57 |
Pre. Close: |
0.5526 |
|
High:
|
0.57 |
Low:
|
0.4975 |
|
Volume:
|
139,362 |
Market Cap:
|
7(M) |
|
|
|
Technical analysis |
as of: 2023-02-03 2:15:37 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 0.67 One year: 0.79 |
| Support: |
Support1: 0.44  Support2: 0.36 |
| Resistance: |
Resistance1: 0.57 Resistance2: 0.67 |
| Pivot: |
0.51 |
| Moving Average: |
MA(5): 0.53  MA(20): 0.49
MA(100): 0.45 MA(250): 1.01 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 69.3 %D(3): 72.4 |
| RSI: |
RSI(14): 58.5 |
| 52-week: |
High: 5.14 Low: 0.33 |
| Average Vol(K): |
3-Month: 188 (K) 10-Days: 92 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CELZ ] has closed below upper band by 42.3%. Bollinger Bands are 1.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.56 - 0.56 |
0.56 - 0.57 |
|
Low:
|
0.51 - 0.52 |
0.52 - 0.52 |
|
Close:
|
0.54 - 0.54 |
0.54 - 0.55 |
|
Company Description |
|
Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine to treat chronic lower back pain; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona. |
Headline News |
Thu, 03 Nov 2022
Creative Medical Technology Holdings Announces FDA Clearance ... - PR Newswire
Thu, 20 Oct 2022
Creative Medical Technology Holdings Develops AlloStem ... - PR Newswire
Mon, 26 Sep 2022
Creative Medical Technology Announces Peer Reviewed ... - PR Newswire
Thu, 28 Jul 2022
Creative Medical Technology Announces Positive Top-Line Results ... - PR Newswire
Mon, 18 Jul 2022
Is it Time to Dump Creative Medical Technology Holdings Inc (CELZ) Stock After it Is Up 15.87% in a Week? - InvestorsObserver
Thu, 14 Jul 2022
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. : Notice of ... - Marketscreener.com
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
6 (M) |
|
% Held by Insiders
|
1.231e+007 (%) |
|
% Held by Institutions
|
2.3 (%) |
|
Shares Short
|
113 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-5.16e+006 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-5 |
|
Return on Assets (ttm)
|
662.4 |
|
Return on Equity (ttm)
|
-27.2 |
|
Qtrly Rev. Growth
|
92750 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
-16.14 |
|
EBITDA (p.s.)
|
8274.42 |
|
Qtrly Earnings Growth
|
-0.2 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-5 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.04 |
|
Price to Cash Flow
|
-50.13 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
46100 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
